动态系统评价的起源与发展

中国药物评价 ›› 2021, Vol. 38 ›› Issue (6): 465-470.

所属专题：专栏——动态系统评价

• 专栏——动态系统评价 • 下一篇

动态系统评价的起源与发展

许建国1，郑卿勇2，程露颖2，3，秦佳欣4，陈涛4，肖月5，6，李江7*，田金徽3，8*

1.兰州大学基础医学院兰州大学循证医学中心，甘肃兰州 730000； 2.兰州大学护理学院兰州大学循证护理中心，甘肃兰州 730000； 3.自贡市第一人民医院，四川自贡 643000； 4.兰州大学第一临床医学院，甘肃兰州 730000； 5.国家卫生健康委卫生发展研究中心，北京 100191； 6.国家卫生健康委国家药物和卫生技术综合评估中心，北京 100191； 7.国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院北京协和医学院肿瘤医院癌症早诊早治办公室，北京 100021; 8.甘肃省循证医学与临床转化重点实验室，甘肃兰州 730000

收稿日期:2021-10-21 修回日期:2021-09-16 出版日期:2021-12-28 发布日期:2021-12-28
基金资助:
中国医学科学院中央级公益性科研院所基本科研专项（项目编号: 2020-PT330-001;项目名称:中国癌症防控循证证据库建立及指导下的癌症筛查效果与可持续发展评价研究）；甘肃省科技厅软科学专项（项目编号:20CX4ZA027;项目名称:中国循证社会科学发展对策研究）；甘肃省科技计划项目（项目编号:20CX9ZA112;项目名称:基于循证医学证据的妊娠期用药数据库管理研究）；国家卫生健康委药政司科研项目（项目编号: CNHDRC-KT-2-2021-49;项目名称:基于我国临床真实世界数据开展儿童药品临床综合评价的标准技术路径及方法研究）

Introduction of the Origin and Development of Living Systematic Review

1.Evidence-Based Medicine Center，School of Basic Medical Sciences，Lanzhou University，Gansu Lanzhou 730000，China; 2.Evidence-based Nursing Center， School of Nursing， Lanzhou University， Gansu Lanzhou 730000，China; 3.Zigong First People′s Hospital， Sichuan Zigong 643000， China; 4.The First Medical College of Lanzhou University，Gansu Lanzhou 730000，China; 5.China National Health Development Research Center， Beijing 100191， China; 6.National Center for Drug and Technology Assessment， Beijing 100191， China; 7.Office of Cancer Screening， National Cancer Center/Cancer Hospital， Chinese Academy of Medical Sciences and Peking Union Medical College， Beijing 100021， China; 8.Key Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province， Gansu Lanzhou 730000， China

Received:2021-10-21 Revised:2021-09-16 Online:2021-12-28 Published:2021-12-28
Contact: lij@cicams.ac.cn E-mail:lij@cicams.ac.cn

摘要/Abstract

摘要： 动态系统评价通过高频次检索及时纳入最新原始研究，保证合并结果时效性并持续更新。本文对动态系统评价的起源与发展进行全面介绍，以期为研究人员了解、研究和应用动态系统评价提供帮助，从而提高我国动态系统评价的产出。

关键词: font-size:medium, ">动态系统评价；起源；发展

Abstract: Living systematic review (LSR) continuously surveils new research evidence through ongoing or frequent searches， and timely incorporates relevant new information into the review， so that the findings of the systematic review remain current. This article gives a comprehensive introduction to the origin and development of LSR， which could help researchers to understand， produce and apply LSR， so as to improve the output of LSR in China.

Key words: Living systematic review, Origin, Development

中图分类号:

许建国, 郑卿勇, 程露颖, 秦佳欣, 陈涛, 肖月, 李江, 田金徽, . 动态系统评价的起源与发展[J]. 中国药物评价, 2021, 38(6): 465-470.

XU Jian-guo, ZHENG Qing-yong, CHENG Lu-ying, QIN Jia-xin, CHEN Tao, XIAO Yue, LI Jiang, TIAN Jin-hui, . Introduction of the Origin and Development of Living Systematic Review[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2021, 38(6): 465-470.

参考文献

[1]Akl EA， Haddaway NR， Rada G， et al. Future of Evidence Ecosystem Series: Evidence synthesis 2.0: when systematic， scoping， rapid， living， and overviews of reviews come together [J]. Journal of clinical epidemiology， 2020， 123: 162-165.
     [2]Gao Y， Yang K， Cai Y， et al. Updating systematic reviews can improve the precision of outcomes: a comparative study [J]. Journal of clinical epidemiology， 2020， 125: 108-119.
     [3]Elliott JH， Turner T， Clavisi O， et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap [J]. PLoS medicine， 2014， 11(2): e1001603.
     [4]Elliott JH， Synnot A， Turner T， et al. Living systematic review: 1. Introduction-the why， what， when， and how [J]. Journal of clinical epidemiology， 2017， 91: 23-30.
     [5]Shojania KG， Sampson M， Ansari MT， et al. How quickly do systematic reviews go out of date? A survival analysis [J]. Annals of internal medicine， 2007， 147(4): 224-233.
     [6]Bastian H， Glasziou P， Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up[J]. PLoS medicine， 2010， 7(9): e1000326.
     [7]Moher D， Tsertsvadze A， Tricco AC， et al. When and how to update systematic reviews [J]. The Cochrane database of systematic reviews， 2008， 1: MR000023.
     [8]Synnot A， Gruen RL， Menon D， et al. A New Approach to Evidence Synthesis in Traumatic Brain Injury: A Living Systematic Review [J]. Journal of neurotrauma， 2021， 38(8): 1069-1071.
     [9]Cnossen MC， Scholten AC， Lingsma HF， et al. Adherence to Guidelines in Adult Patients with Traumatic Brain Injury: A Living Systematic Review [J]. Journal of neurotrauma， 2021， 38(8): 1072-1085.
     [10]Zeiler FA， McFadyen C， Newcombe VFJ， et al. Genetic Influences on Patient-Oriented Outcomes in Traumatic Brain Injury: A Living Systematic Review of Non-Apolipoprotein E Single-Nucleotide Polymorphisms [J]. Journal of neurotrauma， 2021， 38(8): 1107-1123.
     [11]Mondello S， Sorinola A， Czeiter E， et al. Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting to Emergency Departments with Mild Brain Injury: A Living Systematic Review and Meta-Analysis [J]. Journal of neurotrauma， 2021， 38(8): 1086-1106.
     [12]McFadyen CA， Zeiler FA， Newcombe V， et al. Apolipoprotein E4 Polymorphism and Outcomes from Traumatic Brain Injury: A Living Systematic Review and Meta-Analysis [J]. Journal of neurotrauma， 2021， 38(8): 1124-1136.
     [13]Brazinova A， Rehorcikova V， Taylor MS， et al. Epidemiology of Traumatic Brain Injury in Europe: A Living Systematic Review [J]. Journal of neurotrauma， 2021， 38(10):1411-1440.
     [14]Crequit P， Trinquart L， Yavchitz A， et al. Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer [J]. BMC medicine， 2016， 14:8.
     [15]Nikolakopoulou A， Mavridis D， Furukawa TA， et al. Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study [J]. BMJ (Clinical research ed)， 2018， 360: k585.
     [16]Spurling GK， Del Mar CB， Dooley L， et al. Delayed antibiotic prescriptions for respiratory infections [J]. The Cochrane database of systematic reviews， 2017， 9: CD004417.
     [17]Akl EA， Kahale LA， Hakoum MB， et al. Parenteral anticoagulation in ambulatory patients with cancer [J]. The Cochrane database of systematic reviews， 2017， 9: CD006652.
     [18]Hodder RK， Stacey FG， Wyse RJ， et al. Interventions for increasing fruit and vegetable consumption in children aged five years and under [J]. The Cochrane database of systematic reviews， 2017， 9: CD008552.
     [19]Hodder RK， Stacey FG， O′Brien KM， et al. Interventions for increasing fruit and vegetable consumption in children aged five years and under [J]. The Cochrane database of systematic reviews， 2018， 1: CD008552.
     [20]Hodder RK， O′Brien KM， Stacey FG， et al. Interventions for increasing fruit and vegetable consumption in children aged five years and under [J]. The Cochrane database of systematic reviews， 2018， 5: CD008552.
     [21]Hodder RK， O′Brien KM， Stacey FG， et al. Interventions for increasing fruit and vegetable consumption in children aged five years and under [J]. The Cochrane database of systematic reviews， 2019， 11: CD008552
     [22]Hodder RK， O′Brien KM， Tzelepis F， et al. Interventions for increasing fruit and vegetable consumption in children aged five years and under [J]. The Cochrane database of systematic reviews， 2020， 5: CD008552.
     [23]Thomas J， Noel-Storr A， Marshall I， et al. Living systematic reviews: 2. Combining human and machine effort [J]. Journal of clinical epidemiology， 2017， 91:31-37.
     [24]Simmonds M， Salanti G， McKenzie J， et al. Living systematic reviews: 3. Statistical methods for updating meta-analyses [J]. Journal of clinical epidemiology， 2017， 91:38-46.
     [25]Akl EA， Meerpohl JJ， Elliott J， et al. Living systematic reviews: 4. Living guideline recommendations [J]. Journal of clinical epidemiology， 2017， 91:47-53.
     [26]Crequit P， Chaimani A， Yavchitz A， et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis [J]. BMC medicine， 2017， 15(1): 193.
     [27]Sbidian E， Chaimani A， Afach S， et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis [J]. The Cochrane database of systematic reviews， 2020， 1: CD011535.
     [28]Sbidian E， Chaimani A， Garcia-Doval I， et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis [J]. The Cochrane database of systematic reviews， 2021， 4: CD011535.
     [29]Vogel JP， Dowswell T， Lewin S， et al. Developing and applying a ′living guidelines′ approach to WHO recommendations on maternal and perinatal health [J]. BMJ global health， 2019， 4(4): e001683.
     [30]Stroke Foundation. Clinical Guidelines for Stroke Management [EB/OL]. （2019）［2021-09-01］. https://informme.org.au/en/Guidelines/Clinical-Guidelines-for-Stroke-Management.
     [31]Reed N， Zemek R， Dawson J， et al. Living Guideline for Diagnosing and Managing Pediatric Concussion[EB/OL]. (2020)［2021-09-01］. https://braininjuryguidelines.org/pediatricconcussion.
     [32]Wynants L， Van Calster B， Collins GS， et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal [J]. BMJ (Clinical research ed)， 2020， 369:m1328.
     [33]Mackey K， King VJ， Gurley S， et al. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review [J]. Annals of internal medicine， 2020， 173(3): 195-203.
     [34]Schünemann HJ， Khabsa J， Solo K， et al. Ventilation Techniques and Risk for Transmission of Coronavirus Disease， Including COVID-19: A Living Systematic Review of Multiple Streams of Evidence [J]. Annals of internal medicine， 2020， 173(3): 204-216.
     [35]Hernandez AV， Roman YM， Pasupuleti V， et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review [J]. Annals of internal medicine， 2020， 173(4): 287-296.
     [36]Piechotta V， Chai KL， Valk SJ， et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review [J]. The Cochrane database of systematic reviews， 2020， 7: CD013600.
     [37]Deeks JJ， Dinnes J， Takwoingi Y， et al. Antibody tests for identification of current and past infection with SARS-CoV-2 [J]. The Cochrane database of systematic reviews， 2020， 6: CD013652.
     [38]Rochwerg B， Siemieniuk RA， Agoritsas T， et al. A living WHO guideline on drugs for covid-19 [J]. BMJ (Clinical research ed)， 2020， 370:m3379.
     [39]许吉，邓宏勇. 动态系统评价简介 [J]. 中国循证医学杂志， 2020， 20(2): 244-248.
     [40]Shi J， Gao Y， Zhao L， et al. Prevalence of delirium， depression， anxiety， and post-traumatic stress disorder among COVID-19 patients: protocol for a living systematic review [J]. Systematic reviews， 2020， 9(1): 258.
     [41]国际中医药推荐意见制定工作组. 《中西医结合预防与治疗COVID-19的动态循证指南》计划书 [J]. 中国中药杂志， 2021， 46（19）：5117-5122.
     [42]张迁，王琪，后亮瑛，等. 动态指南制订方法及案例介绍 [J]. 中国循证医学杂志， 2021， 21(4): 491-496.
     [43]Juul S， Nielsen EE， Feinberg J， et al. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) [J]. PLoS medicine， 2020， 17(9): e1003293.
     [44]Juul S， Nielsen EE， Feinberg J， et al. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) [J]. PloS one， 2021， 16(3): e0248132.
     [45]Siemieniuk RA， Bartoszko JJ， Ge L， et al. Drug treatments for covid-19: living systematic review and network meta-analysis [J]. BMJ， 2020， 370:m2980.
     [46]Lamontagne F， Agoritsas T， Siemieniuk R， et al. A living WHO guideline on drugs to prevent covid-19 [J]. BMJ (Clinical research ed)， 2021， 372:n526.
     [47]Xu W， Li X， Dozier M， et al. What is the evidence for transmission of COVID-19 by children in schools? A living systematic review [J]. Journal of global health， 2020， 10(2): 021104.
     [48]Riaz IB， He H， Ryu AJ， et al. A Living， Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma [J]. European urology， 2021， S0302-2838(21)00214-1(Online ahead of print).
     [49]Allotey J， Stallings E， Bonet M， et al. Clinical manifestations， risk factors， and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis [J]. BMJ (Clinical research ed)， 2020， 370:m3320.

动态系统评价的起源与发展

Introduction of the Origin and Development of Living Systematic Review

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李川, 杨军令, 程晨, 贾伟伟. 中药新药的药代研究[J]. 中国药物评价, 2023, 40(6): 457-459.
[2]	叶潇, 郑爽#, 林超, 黄舒佳, 王宇, 于敏, 刘颖. 生物分析方法验证及生物样品分析各指导原则间的比较[J]. 中国药物评价, 2023, 40(6): 470-479.
[3]	李丽, 刘婉如, 张征, 江志杰, 李宁. 逐瘀通脉胶囊对大鼠急性局灶性脑缺血再灌注损伤的影响[J]. 中国药物评价, 2023, 40(6): 502-505.
[4]	颜若曦. 《PIC/S生物技术检查备忘录》分析与探讨[J]. 中国药物评价, 2023, 40(6): 537-540.
[5]	甘加明, 邹瑜, 黄丹, 陈冬华, 严全鸿. 基于流池法的氨糖美辛肠溶片体外溶出行为研究[J]. 中国药物评价, 2023, 40(6): 480-484.
[6]	徐桂连, 董斌, 韩春晖, 郝爱鱼. 磷酸苯丙哌林多晶型制备、表征及平衡溶解度研究[J]. 中国药物评价, 2023, 40(6): 489-493.
[7]	代琪, 李康曦, 叶俏波, 文永盛, 许莉, 李及. 僵蚕化学成分、药理作用及毒理学研究进展[J]. 中国药物评价, 2023, 40(5): 402-408.
[8]	赵磊, 杨铭, 王皓, 马彧, 马金刚, 姜大成, 王路宏, 昝珂. 沙棘不同采收期与不同干燥过程真菌毒素的考察及其风险评估[J]. 中国药物评价, 2023, 40(5): 377-383.
[9]	洪淑华, 林琪珊, 柴将红, 潘红炬. 佐匹克隆有关物质及其校正因子影响因素的测定研究[J]. 中国药物评价, 2023, 40(5): 384-388.
[10]	李悦忱, 崔韶婧, 赵月然. 高效液相色谱-柱后光化学衍生法测定活血止痛胶囊中黄曲霉毒素的含量[J]. 中国药物评价, 2023, 40(5): 390-395.
[11]	田洁, 郝爱鱼, 鹿麟, 邹翩, 董斌. 几种药物配伍对常见塑料包装输液产品中不溶性微粒的影响研究[J]. 中国药物评价, 2023, 40(5): 396-401.
[12]	杨艳青, 陈春梅, 陈伟, 吴瑞, 王学昌, 段莲. 信迪利单抗一线治疗晚期非小细胞肺癌的快速卫生技术评估[J]. 中国药物评价, 2023, 40(5): 409-415.
[13]	江依帆, 陈丽萍, 张若钰, 巫培豪, 邱嘉珉, 宣建伟, 毕惠嫦. 抑酸药物的临床综合评价指标体系构建[J]. 中国药物评价, 2023, 40(5): 416-421.
[14]	华敏凡, 宋沧桑, 李兴德, 陆维, 毛盼盼, 王国徽. 服药依从性预测模型临床应用研究进展[J]. 中国药物评价, 2023, 40(5): 422-425.
[15]	黄波, 曹晓明. 等渗与低渗造影剂对老年肾功能损伤患者行冠脉造影术的安全性临床观察[J]. 中国药物评价, 2023, 40(5): 426-429.